Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia (EMPACTA)
NCT04372186Phase 3Completed
- Sponsor
- Genentech
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 6
01
Overview
A Phase 3 trial of tocilizumab in COVID-19 pneumonia, sponsored by Genentech. Started May 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04372186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372186.